Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04618211
Recruitment Status : Recruiting
First Posted : November 5, 2020
Last Update Posted : December 10, 2021
Information provided by (Responsible Party):
Pharvaris Netherlands B.V.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2022